首页|前列腺癌组织中CNN1、ACTG2表达与患者病理特征、预后的关系

前列腺癌组织中CNN1、ACTG2表达与患者病理特征、预后的关系

扫码查看
目的 探讨前列腺癌组织中钙调蛋白1(CNN1)、平滑肌肌动蛋白γ2(ACTG2)表达与患者病理特征、预后的关系.方法 选取2016年12月至2019年12月琼海市中医院收治的98例前列腺癌患者作为研究对象,收集所有患者的癌组织标本(前列腺癌组)及对应的癌旁组织标本(癌旁组).采用免疫组化法检测CNN1、ACTG2在前列腺癌组织、癌旁组织中的表达水平;分析CNN1、ACTG2表达与前列腺癌患者临床病理特征的关系;采用多因素Cox回归分析影响前列腺癌患者预后的危险因素.结果 前列腺癌组的CNN1、ACTG2阳性表达率均低于癌旁组(均P<0.01)o Gleason评分为8~10分、临床分期为T2~3期、术前血清前列腺特异性抗原(PSA)≥4 μg/L、有淋巴结转移及远处转移的前列腺癌患者的CNN1、ACTG2阳性表达率低于Gleason评分为2~7分、临床分期为T1期、术前血清PSA<4 μg/L、无淋巴结转移及无远处转移的患者(均P<0.05)o CNN1阳性表达患者的3年生存率为79.41%,高于CNN1阴性表达患者57.81%(P<0.05);ACTG2阳性表达患者的3年生存率为79.17%,高于ACTG2阴性表达患者52.00%(P<0.05).Gleason评分为2~7分、临床分期为T1期、术前血清PSA<4 pg/L、无淋巴结转移及无远处转移的前列腺癌患者的3年生存率高于Gleason评分为8~10分、临床分期为T2~3期、术前血清PSA≥4μg/L、淋巴结转移及远处转移的患者(均P<0.05).多因素Cox回归分析结果显示,Gleason评分8~10分(HR=2.447,95%CI:1.599~3.745)、有淋巴结转移(HR=2.514,95%CI:1.676~3.772)、CNN1 阴性表达(HR=5.795,95%CI:2.964~11.328)、ACTG2阴性表达(HR=2.912,95%CI:1.823~4.653)是前列腺癌患者预后的危险因素(均P<0.05).结论 CNN1、ACTG2在前列腺癌患者中均呈低表达,且与临床病理特征及预后有关,可作为前列腺癌预后评估的生物学标志物.
The relationship between the expression of CNN1 and ACTG2 in prostate cancer tissues and the pathological characteristics and prognosis of patients
Objective To explore the relationship between the expression of calmodulin 1(CNN1),smooth muscle actin γ2(ACTG2)and the pathological features and prognosis of patients with prostate cancer.Methods A total of 98 patients with prostate cancer admitted to Qionghai Hospi-tal of Traditional Chinese Medicine from December 2016 to December 2019 were selected as the obser-vation group,and the cancer tissue specimens(prostate cancer group)and corresponding paracancer-ous tissue specimens(paracancerous group)of patients with prostate cancer were collected.The ex-pression levels of CNN1 and ACTG2 in prostate cancer tissues and adjacent tissues were detected by immunohistochemistry.The relationship between CNN1 and ACTG2 expression and clinicopathological characteristics of prostate cancer patients were analyzed.Multivariate Cox regression was used to ana-lyze the risk factors affecting the prognosis of patients with prostate cancer.Results The positive ex-pression rates of CNN1 and ACTG2 in prostate cancer group were lower than those in adjacent cancer group(all P<0.01).Gleason score was 8-10,clinical stage was T2-3,preoperative serum prostate-specific antigen(PSA)≥4 μg/L,the positive expression rates of CNN1 and ACTG2 in μg/L patients with lymph node metastasis and distant metastasis were lower than those in patients with Gleason score(2-7 scores),clinical stage(T1),preoperative serum PSA<4 μg/L,no lymph node metastasis and no distant metastasis(all P<0.05).The 3-year survival rate of CNN1 positive expression patients was 79.41%,which was higher than that of CNN1 negative expression patients 57.81%(P<0.05).The 3-year survival rate of ACTG2-positive patients was 79.17%,which was higher than that of ACTG2-negative patients(52.00%)(P<0.05).The 3-year survival rate of prostate cancer patients with Gl-eason score of 2 to 7,clinical stage T1,preoperative serum PSA<4 μg/L,no lymph node metastasis and no distant metastasis was higher than that of patients with Gleason score of 8 to 10,clinical stage of T2 to T3,preoperative serum PSA≥4 μg/L,lymph node metastasis and distant metastasis(all P<0.05).Multivariate Cox regression analysis showed that Gleason score was 8-10 scores(HR=2.447,95%CI:1.599-3.745),lymph node metastasis was present(HR=2.514,95%CI:1.676-3.772),and CNN1 expression was negative(HR=5.795,95%CI:2.964-11.328)and negative expression of ACTG2(HR=2.912,95%CI:1.823-4.653)were prognostic risk factors for prostate cancer patients(all P<0.05).Conclusions CNN1 and ACTG2 are lowly expressed in prostate cancer patients and are related to clinicopathological features and prognosis,which can be used as biological markers for the prognosis evaluation of prostate cancer.

Prostatic NeoplasmsCalmodulin 1Smooth Muscle Actin γ2

符芳颖、黄河、贾非、甘立麒

展开 >

琼海市中医院泌尿外科,琼海 571400

琼海市人民医院泌尿外科,琼海 571400

前列腺肿瘤 钙调蛋白1 平滑肌肌动蛋白

海南省卫生计生行业科研项目

18A200112

2024

国际泌尿系统杂志
中华医学会,湖南省医学会

国际泌尿系统杂志

CSTPCD
影响因子:0.414
ISSN:1673-4416
年,卷(期):2024.44(5)
  • 9